2023-01-25 12:30:00

Foundation Fighting Blindness to Host PRPH2 and Associated Retinal Diseases Workshop

Logo Benzinga
Benzinga
By Pr Newswire

Session to have special translational research emphasis on PRPH2 and inherited macular dystrophies.

COLUMBIA, Md., Jan. 25, 2023 /PRNewswire/ --The Foundation Fighting Blindness, the world's leading organization committed to finding treatments and cures for blinding retinal diseases, in partnership with the Nixon Visions Foundation and the Shiley Eye Institute, at the University of California, San Diego, will host the free in-person PRPH2 and Associated Retinal Diseases Workshop on March 2931, 2023, at the Hilton La Jolla Torrey Pines in San Diego, CA. Registration information can be found at www.FightingBlindness.org/PRPH2Workshop.

The PRPH2 and Associated Retinal Diseases Workshop is designed to bring together leading experts from academia and industry, to discuss openly, and in detail, what is known about PRPH2 disease pathology, disease models, clinical characteristics, and therapeutic approaches. In addition, affected individuals and their families will attend to share their experiences with PRPH2 disease and to hear the latest developments for care, treatment, and strategies for therapies. The workshop will also serve as a launching point for the Nixon Visions Foundation sponsored funding initiative that will provide multiple annual grants to scientific teams addressing high-impact gaps in the field.

Continue read on benzinga.com

Logo Benzinga
Business / FinanceBy Pr Newswire2023-01-24 14:21:00
Company cofounder to discuss use of artificial intelligence and machine learning applications for precision medicine in neurology BOSTON, Jan. 24, 2023...

Logo PR Newswire
HealthPress Release2023-01-24 18:30:00
NEW YORK, Jan. 24, 2023 /PRNewswire/ -- The ophthalmology therapeutics market by product, type, and geography - forecast and analysis 2023-2027 report has...

Logo PR Newswire
HealthPress Release2023-01-25 00:00:00
DUBLIN, Jan. 24, 2023 /PRNewswire/ -- The "Global Photoimmunotherapy Market by Therapeutic Area, End-user, and Region: Competition Forecast and Opportunities...

Logo GlobeNewswire
SciencePress Release2023-01-24 17:12:00
Figure 1 PET scans showing mouse brain before (left) and after (right) MS induction (brain encircled in a dashed white line). The enzyme dCK becomes...

Logo PR Newswire
TechnologyPress Release2023-01-24 15:52:00
NEW YORK, Jan. 24, 2023 /PRNewswire/ -- AEYE Health, a leading AI company for retinal-based diagnostics, is pleased to announce the recent publication of its...

Logo PR Newswire
HealthPress Release2023-01-25 11:30:00
NEW YORK, Jan. 25, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral...

Logo PR Newswire
HealthPress Release2023-01-24 18:00:00
CHICAGO, Jan. 24, 2023 /PRNewswire/ -- According to Arizton's latest research report, the therapeutic contact lenses market is to grow at a CAGR of 5% during...

Logo Benzinga
Business / FinanceBy Pr Newswire2023-01-24 13:55:00
PD GENEration: Mapping the Future of Parkinson's Returns Value to Participants, Physicians and Broader Research Community NEW YORK and MIAMI, Jan. 24, 2023...

Logo GlobeNewswire
SciencePress Release2023-01-24 13:00:00
BOSTON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS)...

Logo The Business Journals
Technology2023-01-25 11:37:59
Recently, the company specializing in Radar-as-a-service and weather forecasting offerings has been, well, flying a bit under the radar until now.

Logo EIN Presswire
Light-Curing Technology for Medical Device Assembly Cutting Edge Light-Cure Products will be Presented, Including a Sneak Peek at a Revolutionary New Technology

Logo Benzinga
Business / FinanceBy Globe Newswire2023-01-25 09:00:00
- Claus Andersson, PhD, joins Rewinds Board of Directors Leuven, Belgium, January 25, 2023 --- Rewind Therapeutics, a company developing first-in-class...

Logo GlobeNewswire
SciencePress Release2023-01-25 07:59:00
Oxurion Announces Second Amendment to Negma Funding Program Leuven, BELGIUM, Boston, MA, US January 25, 202 3 8 :30 am Oxurion NV (Euronext Brussels: OXUR) a...

Logo EIN Presswire
SAINT LOUIS, MISSOURI, USA, January 24, 2023 / EINPresswire.com / -- Immunophotonics, Inc., a clinical-stage biotech company focused on the discovery and...

Logo PR Newswire
Retro frames, aviators, bright colors and tinted lenses are set to lead eyewear trends LOS ANGELES, Jan. 24, 2023 /CNW/ -- Eyebuydirect, the leading online...

Logo PR Newswire
HealthPress Release2023-01-24 15:00:00
DUBLIN, Jan. 24, 2023 /PRNewswire/ -- The "Immunofluorescence Assay Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering....

Logo GlobeNewswire
SciencePress Release2023-01-23 13:00:00
WHITE PLAINS, N.Y., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Iantrek today announced the publication of 12-month clinical results of a novel bio-stenting procedure...

Logo GlobeNewswire
SciencePress Release2023-01-24 13:00:00
SOMERVILLE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (the Company, Finch, or Finch Therapeutics) (Nasdaq: FNCH) today...

Logo GlobeNewswire
SciencePress Release2023-01-24 13:00:00
CARMEL, Ind., Jan. 24, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide...

Logo GlobeNewswire
SciencePress Release2023-01-24 07:19:00
GENOMICS | CELL & GENE THERAPIES | BIOPRODUCTION Genomic Vision renforce sa direction en accueillant Frdric Hammel au poste de D irecteur de s Oprations...